What do Cochrane systematic reviews say about the management of irritable bowel syndrome?
- PMID: 31116276
- PMCID: PMC9721215
- DOI: 10.1590/1516-3180.2018.053740119
What do Cochrane systematic reviews say about the management of irritable bowel syndrome?
Abstract
Background: Irritable bowel syndrome (IBS) is a clinical disorder associated with high socioeconomic burden. Despite its importance, management of IBS remains difficult and several interventions have been hypothesized as beneficial for this condition. This study identified and summarized all Cochrane systematic reviews (SRs) about the effects of interventions for managing IBS patients.
Design and setting: Review of systematic reviews, carried out in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP).
Methods: Review of Cochrane SRs addressing interventions for IBS.
Results: We included six SRs assessing acupuncture, bulking agents, antispasmodics, antidepressants, herbal medicines, homeopathy, hypnotherapy and psychological therapy for IBS. The certainty of evidence ranged from unknown to moderate, mainly due to imprecision in the estimates and high risk of bias from the primary studies included. There was moderate certainty of evidence that acupuncture had no important benefit regarding improvement of symptoms and quality of life, compared with sham acupuncture. There was also very low certainty of evidence that homeopathic asafoetida, used alone or in association with nux, was better than placebo regarding self-reported overall improvement.
Conclusion: There was moderate certainty of evidence that acupuncture had no important benefit regarding improvement of symptoms and quality of life. Further well-designed and well-conducted randomized clinical trials are needed in order to reduce the uncertainties regarding the most commonly used interventions for patients with IBS.
Conflict of interest statement
Similar articles
-
Biofeedback for treatment of irritable bowel syndrome.Cochrane Database Syst Rev. 2019 Nov 12;2019(11):CD012530. doi: 10.1002/14651858.CD012530.pub2. Cochrane Database Syst Rev. 2019. PMID: 31713856 Free PMC article.
-
What do Cochrane systematic reviews say about interventions for insomnia?Sao Paulo Med J. 2018 Nov-Dec;136(6):579-585. doi: 10.1590/1516-3180.2018.0380311018. Sao Paulo Med J. 2018. PMID: 30892489 Free PMC article.
-
INTERVENTIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A REVIEW OF COCHRANE SYSTEMATIC REVIEWS.Arq Gastroenterol. 2021 Jan-Mar;58(1):120-126. doi: 10.1590/S0004-2803.202100000-20. Arq Gastroenterol. 2021. PMID: 33909790
-
What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?Sao Paulo Med J. 2018 Sep-Oct;136(5):472-478. doi: 10.1590/1516-3180.2018.0313210818. Epub 2018 Oct 22. Sao Paulo Med J. 2018. PMID: 30365598 Free PMC article.
-
What do Cochrane systematic reviews say about interventions for treating psoriasis?Sao Paulo Med J. 2018 Jul-Aug;136(4):354-360. doi: 10.1590/1516-3180.0271250618. Epub 2018 Aug 20. Sao Paulo Med J. 2018. PMID: 30133547 Free PMC article. Review.
Cited by
-
Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders.Nat Genet. 2021 Nov;53(11):1543-1552. doi: 10.1038/s41588-021-00950-8. Epub 2021 Nov 5. Nat Genet. 2021. PMID: 34741163 Free PMC article.
-
The Efficacy of the Low-FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) Diet in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.Cureus. 2025 Jan 7;17(1):e77053. doi: 10.7759/cureus.77053. eCollection 2025 Jan. Cureus. 2025. PMID: 39917138 Free PMC article. Review.
References
-
- Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122(4):1140–1156. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources